Home > Healthcare > Medical Devices > Diagnostic Devices > Rapid Influenza Diagnostic Tests (RIDT) Market
Rapid Influenza Diagnostic Tests (RIDT) Market was valued at around USD 1 billion in 2021 and is anticipated to witness 7% CAGR by the end of 2030. The growing adoption of novel influenza diagnostic techniques and the launch of innovative rapid influenza tests by major market players are creating lucrative opportunities for the market.
Similarly, the rising R&D expenditure to offer technologically advanced solutions to diagnose influenza is expected to improve these diagnostic test usage rates across the globe. Wide applications of rapid influenza diagnostic testing coupled with the increasing prevalence of influenza will fuel the rapid influenza diagnostic tests market revenue in the coming years.
The use of these tests for the detection of phenotypic & genotypic characterization of flu viruses has grown rapidly in recent years. Other advantages include eliminating the need for dedicated molecular space and costly capital equipment resulting in the increasing popularity of these influenza tests.
Rapid influenza diagnostic tests refer to tests used in the diagnosis of viral infection caused due to influenza viruses such as influenza A virus, influenza B virus, etc. Healthcare facilities use these influenza diagnostics tools to detect the disease, monitor the influenza progression, and offer optimal therapeutics. Rapid influenza diagnostic testing provides fast, precise, specific, & cost-effective diagnosis, and a broad array of these tests is available that finds application against several influenza viruses.
However, the lack of experienced professionals and advanced infrastructure in low-resource settings such as remote areas, rural areas, and urban slums interfere with the implementation of influenza testing in developing countries such as India, China, and Mexico among others. It is difficult to maintain access to quality health care services in remote and rural areas owing to a lack of transportation and communication.
Report Attribute | Details |
---|---|
Base Year: | 2021 |
Rapid Influenza Diagnostic Tests Market Size in 2021: | USD 1,009.7 million |
Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 7.0% |
2030 Value Projection: | USD 1,920.0 million |
Historical Data for: | 2017 to 2021 |
No. of Pages: | 80 |
Tables, Charts & Figures: | 81 |
Segments covered: | End-use and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Moreover, skilled technicians and experienced physicians are required for rapid influenza diagnostic tests to avoid the risk of false interpretations. Developing countries face the challenge of shortages of doctors and experienced healthcare professionals, especially in rural and remote areas. The physician-to-patient ratio in China is 1.49:1000 that is much lower as compared to the developed countries.
The lack of experienced professionals and advanced infrastructure in developing countries could result in increased morbidity and mortality hampering the rapid influenza diagnostic tests market growth over the forecast period.
The recent outbreak of COVID-19 has negatively impacted the rapid influenza diagnostic tests market growth. The increased demand for coronavirus testing has highly impacted other disease testing services including rapid influenza diagnostic tests. In 2020, the prevalence as well as the mortality rate due to COVID-19 was significant and people preferred to avoid any other treatment or diagnosis procedures at healthcare facilities.
The production facilities and supply chain were highly impacted owing to the high volume of COVID-19 patients & worldwide lockdown scenario. Most of the leading nations worldwide imposed a total lockdown and the total emphasis was shifted to the rise in demand for essential products & services, that hindered the manufacturing and adoption of rapid influenza diagnostic testing products.
However, in 2021, the technological advancements and incorporation of telemedicine in influenza infection diagnosis have augmented target disease diagnosis compliance and promoted the acceptance of rapid influenza diagnostic testing products. Also, among COVID-19 infected patients, influenza was related to an increased risk of infection and hospitalization, with a heightened risk of respiratory failure. Hence, the COVID-19 has impacted the market in the shorter run; however, the decreasing COVID-19 infection rates & patients and growing product demand is expected to drive market growth in the forthcoming period.